Epinal

This research aims to better understand how pregnancy affects women with multiple sclerosis MS and related neurological conditions, including neuromyelitis optica and myelin oligodendrocyte glycoprotein antibody-related disorders. The study focuses on important questions about the use of disease-modifying drugs during pregnancy, the effects on the mothers health and disability, the childs health, breastfeeding, and pain management during delivery. It is a national, prospective, observational study conducted within the French MS cohort called Observatoire Franais de la Sclrose en Plaque OFSEP. Women with MS or related disorders who are pregnant will be followed throughout their pregnancy and for one year after giving birth. Their children will also be monitored until they reach six years of age. There is no intervention or treatment given as part of this study instead, it collects detailed information on the course of MS during pregnancy and postpartum, including any use or discontinuation of disease-modifying drugs and other pregnancy-related factors. Participants will have regular follow-ups during pregnancy and postpartum to assess their health and any treatment-related side effects. Researchers will collect data on relapses, disability progression, breastfeeding, and use of pain relief during delivery. Children born to these women will be observed for up to six years to evaluate long-term outcomes. The main outcomes measured include the number of treatment-related adverse events during pregnancy and postpartum, helping to improve knowledge for neurologists and families regarding MS and pregnancy.

Researchers are collecting biological samples to improve diagnosis and treatment of rare neuroimmune disorders affecting the central and peripheral nervous system. These disorders include Paraneoplastic Neurological Syndromes PNS and Autoimmune Encephalitis AE, which involve immune system activity. The study aims to support faster and more accurate diagnosis, benefiting patients with these conditions by enhancing future treatment approaches. Participants diagnosed with PNS or AE will have biological samples collected once, including blood and possibly cerebrospinal fluid if available. Blood samples will be used to obtain serum, buffy coat, plasma, and peripheral blood mononuclear cells. If cerebrospinal fluid is drawn for diagnosis, any remaining sample will be stored. This collection will occur during a single visit, and samples will be stored for up to 10 years. During the study, participants will provide consent and undergo sample collection only once. Researchers will monitor the blood samples and cerebrospinal fluid biocollection over 10 years. The study emphasizes scientific collaboration and ongoing research to improve understanding and treatment of these neurological disorders. Participation duration focuses on the collection and long-term storage of biological samples.